Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
A targeting technology developed by Australian company Starpharma Holdings has delivered tumor levels of Sanofi Aventis' anticancer drug docetaxel (Taxotere) that are higher and longer-lasting than those seen with the current formulation.
Under the terms of the agreement, AstraZeneca will test Starpharma drug-dendrimer conjugate molecules as potential anti-cancer agents.
Eli Lilly ($LLY) is doubling down on efforts to tap into other firms' drug delivery technology for its own development efforts. The pharmaceutical giant will expand a 2010 deal with Australia's
Investigators for Australia's Starpharma and the Monash Institute of Pharmaceutical Sciences have picked up a sizeable new grant to finance a fresh round of research on the use of dendrimers for